Estimation of screening test (Hemoccult) sensitivity in colorectal cancer mass screening
- PMID: 11384097
- PMCID: PMC2363664
- DOI: 10.1054/bjoc.2001.1752
Estimation of screening test (Hemoccult) sensitivity in colorectal cancer mass screening
Abstract
3 controlled cohorts of mass-screening for colorectal cancer using a biennial faecal occult blood (HemoccultII test on well-defined European populations have demonstrated a 14% to 18% reduction in specific mortality. We aimed to estimate the sensitivity (S) of this HemoccultII test and and also mean sojourn time (MST) from French colorectal mass-screening programme data. 6 biennial screening rounds were performed from 1988 to 1998 in 45 603 individuals aged 45-74 years in Saône-et-Loire (Burgundy, France). The prevalent/incidence ratio was calculated in order to obtain a direct estimate of the product S.MST. The analysis of the proportional incidence and its modelling was used to derive an indirect estimate of S and MST. The product S.MST was higher for males than females and higher for left colon than either the right colon or rectum. The analysis of the proportional incidence confirmed the result for subsites but no other significant differences were found. The sensitivity was estimated at 0.57 and the MST at 2.56 years. This study confirms that the sensitivity of the Hemoccult test is relatively low and that the relatively short sojourn time is in favour of annual screening.
Copyright 2001 Cancer Research Campaign.
Similar articles
-
[Performance of the Hemoccult test in the screening of colorectal cancer and adenoma. Results of 5 screening campaigns in Saône-et-Loire].Gastroenterol Clin Biol. 1999 May;23(5):475-80. Gastroenterol Clin Biol. 1999. PMID: 10429850 French.
-
Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds.Scand J Gastroenterol. 2004 Sep;39(9):846-51. doi: 10.1080/00365520410003182. Scand J Gastroenterol. 2004. PMID: 15513382 Clinical Trial.
-
Fecal occult blood testing: clinical value and limitations.Gastroenterologist. 1998 Mar;6(1):66-78. Gastroenterologist. 1998. PMID: 9531118 Review.
-
Faecal occult blood screening and reduction of colorectal cancer mortality: a case-control study.Br J Cancer. 1999 Feb;79(3-4):680-3. doi: 10.1038/sj.bjc.6690107. Br J Cancer. 1999. PMID: 10027349 Free PMC article.
-
[Faecal occult blood test and mass screening for colorectal cancer].Nihon Rinsho. 2003 Sep;61 Suppl 7:201-6. Nihon Rinsho. 2003. PMID: 14574882 Review. Japanese. No abstract available.
Cited by
-
Sensitivity of latex agglutination faecal occult blood test in the Florence District population-based colorectal cancer screening programme.Br J Cancer. 2007 Jun 4;96(11):1750-4. doi: 10.1038/sj.bjc.6603759. Epub 2007 Apr 24. Br J Cancer. 2007. PMID: 17453007 Free PMC article.
-
Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries.BMC Cancer. 2006 May 24;6:136. doi: 10.1186/1471-2407-6-136. BMC Cancer. 2006. PMID: 16723013 Free PMC article.
-
Contribution of the OC Sensor® immunoassay in comparison to the Hemoccult II® guaiac-test in organized colorectal cancer screening.Eur J Epidemiol. 2019 Feb;34(2):163-172. doi: 10.1007/s10654-018-0471-z. Epub 2018 Dec 8. Eur J Epidemiol. 2019. PMID: 30536183
-
Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths.N Engl J Med. 2012 Feb 23;366(8):687-96. doi: 10.1056/NEJMoa1100370. N Engl J Med. 2012. PMID: 22356322 Free PMC article.
-
Estimated mean sojourn time associated with hemoccult SENSA for detection of proximal and distal colorectal cancer.Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1722-30. doi: 10.1158/1055-9965.EPI-12-0561. Epub 2012 Aug 21. Cancer Epidemiol Biomarkers Prev. 2012. PMID: 22911331 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical